Survivin: A molecular biomarker in cancer.
Survivin: A molecular biomarker in cancer.
复制标题
DOI：
10.4103/0971-5916.159250
复制
发表时间：
2015-04
期刊：
影响因子：
--
通讯作者：
Mittal RD
中科院分区：
文献类型：
--
作者：
Jaiswal PK;Goel A;Mittal RD
Survivin是凋亡抑制蛋白家族的一员，可抑制半胱天冬酶并阻断细胞死亡，在大多数癌症中高度表达，并与不良临床结局相关。通过分子谱分析，生存素一直被鉴定为与高肿瘤级别癌症、不同疾病存活率和复发相关。生存素基因的多态性正在成为研究疾病生物学的有力工具，并有可能用于疾病预后和诊断。生存素基因多态性也被报道影响肿瘤的侵袭性以及癌症患者的生存。与正常组织相比，存活素在癌细胞中的差异表达及其在许多细胞途径中作为节点蛋白的作用使其成为不同治疗的高靶标。这篇综述讨论了生存素在人类癌症中的复杂电路和生存素的基因变体，并强调了针对这一重要蛋白质的新疗法。
Survivin, a member of the inhibitor of apoptosis (IAP) protein family that inhibits caspases and blocks cell death, is highly expressed in most cancers and is associated with a poor clinical outcome. Survivin has consistently been identified by molecular profiling analysis to be associated with high tumour grade cancers, different disease survival and recurrence. Polymorphisms in the survivin gene are emerging as powerful tools to study the biology of the disease and have the potential to be used in disease prognosis and diagnosis. The survivin gene polymorphisms have also been reported to influence tumour aggressiveness as well as survival of cancer patients. The differential expression of survivin in cancer cells compared to normal tissues and its role as a nodal protein in a number of cellular pathways make it a high target for different therapeutics. This review discusses the complex circuitry of survivin in human cancers and gene variants of survivin, and highlights novel therapy that targets this important protein.